Table 3 Treatments and 12-month outcomes of neovascular age-related macular degeneration by angiographic subtypes.
Variables | Classic CNV n = 14 | Occult CNV n = 20 | MCV n = 60 | PCV n = 76 | RAP n = 35 | P-value |
|---|---|---|---|---|---|---|
Mean numbers of PDT | 0 | 0.20 ± 0.41 | 0.22 ± 0.52 | 0.20 ± 0.52 | 0.09 ± 0.28 | 0.395 |
Mean numbers of anti-VEGF treatment | 4.29 ± 3.12 | 5.40 ± 2.09 | 4.50 ± 2.53 | 4.46 ± 2.31 | 4.37 ± 2.47 | 0.577 |
BCVA, baseline, Snellen (logMAR) | 20/166 (0.91) | 20/125 (0.79) | 20/100 (0.69) | 20/90 (0.65) | 20/133 (0.81) | 0.385 |
BCVA, 12 months, Snellen (logMAR) | 20/153 (0.89) | 20/105 (0.71) | 20/80 (0.60) | 20/62 (0.49) | 20/111 (0.75) | 0.046 |
CST, baseline, μm | 314.4 ± 133.3 | 333.8 ± 109.8 | 301.2 ± 90.1 | 310.3 ± 94.1 | 328.7 ± 101.3 | 0.637 |
CST, 12 months, μm | 244.6 ± 73.7 | 276.2 ± 117.9 | 257.6 ± 67.9 | 243.8 ± 66.9 | 241.1 ± 56.3 | 0.391 |
